Market Cap 14.05B
Revenue (ttm) 680.85M
Net Income (ttm) -74.68M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 187.05
Profit Margin -10.97%
Debt to Equity Ratio 0.00
Volume 16,062,900
Avg Vol 2,581,098
Day's Range N/A - N/A
Shares Out 106.52M
Stochastic %K 77%
Beta 0.46
Analysts Sell
Price Target $125.45
JarvisFlow
JarvisFlow Jun. 4 at 10:00 AM
Mizuho has updated their rating for Intra-Cellular Therapies ( $ITCI ) to Outperform with a price target of 140.
0 · Reply
megamaven
megamaven Jun. 4 at 1:18 AM
$IBRX $ITCI $ADMA $BMY $JNJ the truth about baby bio stocks - 98% fail. Short any NEW bio, and you'll make money 98% of the time. Rare exceptions: adma was left for dead. Now trading in the $20 range. $ITCI bought out in the $130 range. IBRX now $2.70 due to dilution and negative cash value. Cash is our future, and dilution will end after warrants are exercised. Current holders restricting lending their shares and cash, baby cash will get the explosive upside That is inevitable. Big pharma, here we come. Not with a buyout. Joining ranks due to cash generated.
1 · Reply
Dcainedwr
Dcainedwr May. 29 at 5:50 PM
$SNDX I’ve been investing in bio Pharma for about six years. I have a question for more experienced, astute investors: what are the chances we might see a repeat of what happened with $ITCI? I wouldn’t be mad at that; I made a ton of money when $ITCI got bought. (After reviewing a lot of comments here; taking a long look at institutional investors; and additional research, I just began investing in this company mid May. I had 2 entry points: 9.05 & 9.85)
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 25 at 12:30 AM
$SWTX is being acquired at the lowest multiple of cumulative 10-year projected revenues & gross margin per acquiree management when compared to 6 peers on the attachment with a like growth profile & $1B in annual sales within 5 years of M&A A common risk cited to SWTX's valuation potential was uncertainty around the unpublished royalty rate due Pfizer. SWTX mgmt prepared a gross margin forecast @ ~84% of sales SWTX was acquired @ 0.31X its cumulative 10-year projected gross margin. These 6 peers were acquired at 0.36X to 0.83X their cumulative 10-year projected gross margins. What else can be said? This is further disappointing b/c SWTX had 2 FDA approved drugs that otherwise , in theory, lower risk which in turn should increase M&A value We'd truly appreciate if any investor is aware of any peer with a like profile acquired at a lower multiple of projected 10-year gross margin. What are we missing? $ITCI & $IMGN appear the most recent peer M&A. $XBI $NBI
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 24 at 8:48 PM
The attachment compares $LEGN actual FY23 & FY24 as well as FY25 - FY34 analyst consensus revenue estimates to the like projected revenues as prepared by $ITCI & $IMGN management when both were acquired recently. Analysts project LEGN to generate $29.9B in cumulative revenues between FY25 & FY34 yet LEGN trades for 0.16X this estimate where the 2 were acquired at 0.41X & 0.69X their like projections. FWIW LEGN generates lower gross margins but because they are a 50/50 partner with $JNJ at what point do they need to consider what is best for shareholders. Also FWIW ITCI & IMGN were acquired at the highest revenue multiples of all recent peer commercial-stage bio M&A transactions over the last 5 years. Put simply, this may not be an apples to apples comparison but any feedback from LEGN investors would be humbly appreciated.
2 · Reply
Peterson28
Peterson28 Apr. 22 at 1:17 PM
$ITCI $JNJ $NBIX $XBI The whole sector’s M&A multiple has come down significantly. No one is willing to pay that high premium as the DCF discount rate has spiked.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 22 at 12:38 PM
$NBIX trades for a market cap of $10B at $100/share. NBIX is profitable & has $2B in cash so its enterprise value is just over $8B. By comparison, $ITCI was acquired by $JNJ for an enterprise value of $13.6B. NBIX generated 4X more in product sales than ITCI in FY23 & FY24 and at higher gross margins. NBIX is expected to generate 1.3X more in revenues between FY25 & FY34 than ITCI. If NBIX was acquired at the same multiple of cumulative 10-year projected sales as ITCI, this would be an enterprise of roughly $18B & a market cap of roughly $20B (double where NBIX trades today). Because NBIX generates a higher gross margin than ITCI, it could be argued NBIX warrants a higher multiple. The attached graph compares actual FY23 & FY24 NBIX revenues v ITCI as well as 10 year projected revenues. $XBI This is not investment advice. For all we know, NBIXC projected revenues are inaccurate.
0 · Reply
Halo66
Halo66 Apr. 8 at 1:26 PM
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 4 at 2:57 PM
now to deal with u $ITCI !!!!!!!!!!!!!!!!!
0 · Reply
swingingtech
swingingtech Apr. 2 at 7:28 PM
$JNJ $ITCI https://wallstreetwaves.com/stock-of-the-day-will-johnson-johnson-rally-the-sell-off-may-have-ended/
0 · Reply
Latest News on ITCI
Top 4 Health Care Stocks You May Want To Dump In Q1

Jan 21, 2025, 6:06 AM EST - 5 months ago

Top 4 Health Care Stocks You May Want To Dump In Q1

BBIO BSX ISRG


Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal

Jan 13, 2025, 3:13 PM EST - 5 months ago

Johnson & Johnson to Acquire Intra-Cellular in $15 Billion Deal

JNJ


J&J to buy Intra-Cellular Therapies for $14.6 billion

Jan 13, 2025, 6:38 AM EST - 5 months ago

J&J to buy Intra-Cellular Therapies for $14.6 billion

JNJ


This Stock Is Soaring Amid J&J Takeover Report

Jan 13, 2025, 5:41 AM EST - 5 months ago

This Stock Is Soaring Amid J&J Takeover Report


Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19, 2024, 2:08 AM EDT - 1 year ago

Intra-Cellular Brightens MDD Outlook With Caplyta Success


JarvisFlow
JarvisFlow Jun. 4 at 10:00 AM
Mizuho has updated their rating for Intra-Cellular Therapies ( $ITCI ) to Outperform with a price target of 140.
0 · Reply
megamaven
megamaven Jun. 4 at 1:18 AM
$IBRX $ITCI $ADMA $BMY $JNJ the truth about baby bio stocks - 98% fail. Short any NEW bio, and you'll make money 98% of the time. Rare exceptions: adma was left for dead. Now trading in the $20 range. $ITCI bought out in the $130 range. IBRX now $2.70 due to dilution and negative cash value. Cash is our future, and dilution will end after warrants are exercised. Current holders restricting lending their shares and cash, baby cash will get the explosive upside That is inevitable. Big pharma, here we come. Not with a buyout. Joining ranks due to cash generated.
1 · Reply
Dcainedwr
Dcainedwr May. 29 at 5:50 PM
$SNDX I’ve been investing in bio Pharma for about six years. I have a question for more experienced, astute investors: what are the chances we might see a repeat of what happened with $ITCI? I wouldn’t be mad at that; I made a ton of money when $ITCI got bought. (After reviewing a lot of comments here; taking a long look at institutional investors; and additional research, I just began investing in this company mid May. I had 2 entry points: 9.05 & 9.85)
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 25 at 12:30 AM
$SWTX is being acquired at the lowest multiple of cumulative 10-year projected revenues & gross margin per acquiree management when compared to 6 peers on the attachment with a like growth profile & $1B in annual sales within 5 years of M&A A common risk cited to SWTX's valuation potential was uncertainty around the unpublished royalty rate due Pfizer. SWTX mgmt prepared a gross margin forecast @ ~84% of sales SWTX was acquired @ 0.31X its cumulative 10-year projected gross margin. These 6 peers were acquired at 0.36X to 0.83X their cumulative 10-year projected gross margins. What else can be said? This is further disappointing b/c SWTX had 2 FDA approved drugs that otherwise , in theory, lower risk which in turn should increase M&A value We'd truly appreciate if any investor is aware of any peer with a like profile acquired at a lower multiple of projected 10-year gross margin. What are we missing? $ITCI & $IMGN appear the most recent peer M&A. $XBI $NBI
1 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 24 at 8:48 PM
The attachment compares $LEGN actual FY23 & FY24 as well as FY25 - FY34 analyst consensus revenue estimates to the like projected revenues as prepared by $ITCI & $IMGN management when both were acquired recently. Analysts project LEGN to generate $29.9B in cumulative revenues between FY25 & FY34 yet LEGN trades for 0.16X this estimate where the 2 were acquired at 0.41X & 0.69X their like projections. FWIW LEGN generates lower gross margins but because they are a 50/50 partner with $JNJ at what point do they need to consider what is best for shareholders. Also FWIW ITCI & IMGN were acquired at the highest revenue multiples of all recent peer commercial-stage bio M&A transactions over the last 5 years. Put simply, this may not be an apples to apples comparison but any feedback from LEGN investors would be humbly appreciated.
2 · Reply
Peterson28
Peterson28 Apr. 22 at 1:17 PM
$ITCI $JNJ $NBIX $XBI The whole sector’s M&A multiple has come down significantly. No one is willing to pay that high premium as the DCF discount rate has spiked.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Apr. 22 at 12:38 PM
$NBIX trades for a market cap of $10B at $100/share. NBIX is profitable & has $2B in cash so its enterprise value is just over $8B. By comparison, $ITCI was acquired by $JNJ for an enterprise value of $13.6B. NBIX generated 4X more in product sales than ITCI in FY23 & FY24 and at higher gross margins. NBIX is expected to generate 1.3X more in revenues between FY25 & FY34 than ITCI. If NBIX was acquired at the same multiple of cumulative 10-year projected sales as ITCI, this would be an enterprise of roughly $18B & a market cap of roughly $20B (double where NBIX trades today). Because NBIX generates a higher gross margin than ITCI, it could be argued NBIX warrants a higher multiple. The attached graph compares actual FY23 & FY24 NBIX revenues v ITCI as well as 10 year projected revenues. $XBI This is not investment advice. For all we know, NBIXC projected revenues are inaccurate.
0 · Reply
Halo66
Halo66 Apr. 8 at 1:26 PM
0 · Reply
Love_To_Learn
Love_To_Learn Apr. 4 at 2:57 PM
now to deal with u $ITCI !!!!!!!!!!!!!!!!!
0 · Reply
swingingtech
swingingtech Apr. 2 at 7:28 PM
$JNJ $ITCI https://wallstreetwaves.com/stock-of-the-day-will-johnson-johnson-rally-the-sell-off-may-have-ended/
0 · Reply
JarvisFlow
JarvisFlow Apr. 2 at 2:33 PM
Cantor Fitzgerald updates rating for Intra-Cellular Therapies ( $ITCI ) to Neutral, target set at 132.
0 · Reply
TheOptionsOracleUSA
TheOptionsOracleUSA Apr. 2 at 1:37 PM
$JNJ Johnson & Johnson has completed its acquisition of Intra-Cellular Therapies ($ITCI)
1 · Reply
cornelius_zephyr
cornelius_zephyr Apr. 2 at 12:41 AM
$ITCI trading halted. Are we all done here?
0 · Reply
Okadarlan
Okadarlan Apr. 1 at 10:05 PM
$ITCI feels like a short entry from here.
0 · Reply
CubensisMoya
CubensisMoya Apr. 1 at 2:01 PM
$JNJ bankruptcy filing, yet they are acquiring $ITCI ? maybe the deal won't even happen
0 · Reply
Wyckly670
Wyckly670 Mar. 31 at 4:51 AM
$DERM $ ARQT potential M&A targets : $ITCI $CMRX $CKPT $SWTX ?
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 30 at 11:03 PM
$ITCI Digging ITCI's pipeline. Long-acting lumateperone could be game-changer. Watching Phase 2 trials for anxiety and Alzheimer's. Potential big moves ahead with neuroplastogens program. Keeping position and monitoring closely. insightful writeup: https://beyondspx.com/article/intra-cellular-therapies-inc-itci-a-promising-contender-in-the-pharmaceutical-landscape
1 · Reply
MAs_Crxss
MAs_Crxss Mar. 30 at 9:22 PM
$ITCI 130 strike puts are worth Pennies… might take a gamble on November puts
1 · Reply
cornelius_zephyr
cornelius_zephyr Mar. 28 at 9:42 PM
$ITCI curious why anyone is still buying this now, for a 20 cent gain. I bought at 127, and sold yesterday.
2 · Reply
Daniech0514
Daniech0514 Mar. 28 at 4:43 PM
$ITCI vote approved pay day is coming soon.
0 · Reply
megamaven
megamaven Mar. 18 at 4:11 PM
$ITCI shame management agreed to sell. Way undervalued. Just donated 500 shares. Holding 2500 in pension.
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Mar. 18 at 3:47 PM
The attachment graphs $NBIX FY23 & FY24 actual revenues & FY25-FY34 analyst revenue estimates compared to the like $ITCI data points except ITCI FY25-FY34 revenue estimates are per ITCI management per ITCI's 14A filing dated 2/18/25 NBIX analysts forecast NBIX to generate 1.4X more in collective revenues between FY25 & FY34 than ITCI per ITCI management NBIX generated gross margins at 99% in FY24 v ITCI at 92%. If NBIX can maintain 98% gross margins (FY23's rate) then NBIX would generate 1.5X more in cumulative gross margins over the same 10-year period If Ingrezza & Crinessity generate more 1.4X more revenues than Caplyta, then is it reasonable to assume NBIX would be worth 1.4X more if acquired. Ingrezza & Caplyta are patented thru FY38. This is not investment advice ITCI was acquired for an enterprise value of $13.6B ($14.6B M&A price less $1.0B ITCI cash on hand). NBIX's fully diluted MC = ~$11.4B & EV is ~$9.1B at $110/sh $XBI
1 · Reply